Home

Products

Alethia is focusing on bone loss in acute disorders, invasive carcinomas and on cancer-associated epithelial-to-mesenchymal transition, three areas for which there are very few therapeutic options.

AB-25E9 – inhibition of bone degradation

Alethia is developing a first-in-class bone antiresorptive for the treatment of bone loss in acute disorders such a hypercalcemia of malignancy, bone and cartilage loss in inflammatory disorders and severe osteoporosis. Read more about AB-25E9

AB-3A4 – invasive carcinomas

Alethia is developing a therapeutic monoclonal antibody for the treatment of ovarian cancer and other invasive carcinomas such as triple-negative breast tumors and renal cancer. AB-3A4 is an IgG1 monoclonal antibody against KAAG-1, a cell-surface protein involved in tumor invasion. Read more about AB-3A4

AB-16B5 – inhibition of EMT

Alethia is developing an inhibitor of EMT for the treatment of invasive carcinomas. AB-16B5 is a humanized IgG2 antibody against an EMT-inducing form of secreted clusterin (sCLU). AB-16B5 very efficiently blocks EMT and pre-clinical data indicate that animals xenografted with various carcinoma cells show an increase of response to standard of care chemotherapy as well as a reduction of invasion. Read more about AB-16B5

News

  • October 9, 2013 Alethia Biotherapeutics Announces the Issuance of a Patent for the Use of Anti-Siglec-15 Antibodies Alethia PR 131009 EN...
  • May 29, 2013 Alethia Biotherapeutics Announce Entry into Licensing and Research Agreements for its Inhibitor of EMT with IBC Generium Alethia 130529 EN...
  • May 16, 2013 Alethia Biotherapeutics Announces the Issuance of a United States Patent for Monoclonal Antibodies Targeting Secreted Clusterin for Inhibition of EMT Alethia 130516 EN...

Events

  • May 30 - June 3, 2014 Alethia Biotherapeutics to be part of the ASCO Annual Meeting at the McCormick Place, Chicago, Illinois. Drs.  Mario Filion  and Gilles Tremblay will be in attendance....
  • April 5 - 9, 2014 Alethia Biotherapeutics to present at the AACR Annual Meeting 2014 at the San Diego Convention Center, San Diego, California.  Drs. Mario Filion and Gilles Tremblay will present data on: AB-3A4: A novel KAAG1-targeting antibody-drug conjugate is ac...
  • January 13 -16, 2014 Alethia Biotherapeutics to be part of the Biotech Showcase 2014, Parc 55 Windham Hotel, San Francisco, USA. Yves Cornellier and Mario Filion will be in attendance....